CD133 is a transmembrane glycoprotein widely recognized as a crucial marker of malignant tumor recurrence and poor prognosis, and it is expressed in a variety of malignant tumors, including hepatocellular carcinoma, pancreatic cancer, and gastric cancer [81]. Here, PROM1 is linked to cancer.